Cargando…

Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine

Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Guanlin, Li, Ying, Li, Shicheng, Liu, Hongxia, Xu, Fei, Lai, Xiaohuan, Zhang, Qiong, Xu, Jingxiang, Wan, Shaogui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481798/
https://www.ncbi.nlm.nih.gov/pubmed/34603382
http://dx.doi.org/10.3389/fgene.2021.719451
_version_ 1784576760046682112
author Zhou, Guanlin
Li, Ying
Li, Shicheng
Liu, Hongxia
Xu, Fei
Lai, Xiaohuan
Zhang, Qiong
Xu, Jingxiang
Wan, Shaogui
author_facet Zhou, Guanlin
Li, Ying
Li, Shicheng
Liu, Hongxia
Xu, Fei
Lai, Xiaohuan
Zhang, Qiong
Xu, Jingxiang
Wan, Shaogui
author_sort Zhou, Guanlin
collection PubMed
description Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stratify patients who may benefit from this treatment are needed. In this study, we aimed to evaluate whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content was associated with the outcome of HCC patients, especially of those who received the combination treatment of TACE and TCM. Univariate and multivariate Cox analyses were conducted to evaluate the association between ccf-mtDNA content and the overall survival of HBV-HCC patients. Kaplan–Meier analysis was used to compare the survival differences between patients with low and high ccf-mtDNA content. In a hospital-based cohort with 141 HBV-HCC patients, there was no statistically significant association between the ccf-mtDNA content and the overall survival of HBV-HCC patients in the univariate analysis, but a borderline significant association was found in the multivariate analyses. In a subcohort of 50 HBV-HCC patients who received TACE and TCM treatment, high ccfDNA content conferred an increased death risk with a hazard ratio of 4.01 (95% confidence interval: 1.25–12.84, p = 0.019) in the multivariate analysis. Kaplan–Meier survival analysis also showed that patients with high ccf-mtDNA content had unfavorable survival (log rank p = 0.097). Our findings suggest that ccf-mtDNA content is a potential non-invasive prognostic biomarker in HCC patients receiving TACE and TCM treatment.
format Online
Article
Text
id pubmed-8481798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84817982021-10-01 Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine Zhou, Guanlin Li, Ying Li, Shicheng Liu, Hongxia Xu, Fei Lai, Xiaohuan Zhang, Qiong Xu, Jingxiang Wan, Shaogui Front Genet Genetics Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stratify patients who may benefit from this treatment are needed. In this study, we aimed to evaluate whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content was associated with the outcome of HCC patients, especially of those who received the combination treatment of TACE and TCM. Univariate and multivariate Cox analyses were conducted to evaluate the association between ccf-mtDNA content and the overall survival of HBV-HCC patients. Kaplan–Meier analysis was used to compare the survival differences between patients with low and high ccf-mtDNA content. In a hospital-based cohort with 141 HBV-HCC patients, there was no statistically significant association between the ccf-mtDNA content and the overall survival of HBV-HCC patients in the univariate analysis, but a borderline significant association was found in the multivariate analyses. In a subcohort of 50 HBV-HCC patients who received TACE and TCM treatment, high ccfDNA content conferred an increased death risk with a hazard ratio of 4.01 (95% confidence interval: 1.25–12.84, p = 0.019) in the multivariate analysis. Kaplan–Meier survival analysis also showed that patients with high ccf-mtDNA content had unfavorable survival (log rank p = 0.097). Our findings suggest that ccf-mtDNA content is a potential non-invasive prognostic biomarker in HCC patients receiving TACE and TCM treatment. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481798/ /pubmed/34603382 http://dx.doi.org/10.3389/fgene.2021.719451 Text en Copyright © 2021 Zhou, Li, Li, Liu, Xu, Lai, Zhang, Xu and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zhou, Guanlin
Li, Ying
Li, Shicheng
Liu, Hongxia
Xu, Fei
Lai, Xiaohuan
Zhang, Qiong
Xu, Jingxiang
Wan, Shaogui
Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title_full Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title_fullStr Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title_full_unstemmed Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title_short Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
title_sort circulating cell-free mtdna content as a non-invasive prognostic biomarker in hcc patients receiving tace and traditional chinese medicine
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481798/
https://www.ncbi.nlm.nih.gov/pubmed/34603382
http://dx.doi.org/10.3389/fgene.2021.719451
work_keys_str_mv AT zhouguanlin circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT liying circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT lishicheng circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT liuhongxia circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT xufei circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT laixiaohuan circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT zhangqiong circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT xujingxiang circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine
AT wanshaogui circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine